Wendel (FRA:WIS)
Germany · Delayed Price · Currency is EUR 84.10
-8.90 (-9.57%)
Last updated: Jul 31, 2025
Inozyme Pharma Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | -90 | 293.9 | 142.4 | 656.3 | 1,047 | -264.1 | Upgrade |
Depreciation & Amortization | 451.2 | 333.6 | 325.8 | 332.4 | 371.8 | 604.2 | Upgrade |
Other Amortization | 5.9 | 5.9 | 7.3 | 9.9 | 14.4 | 17.3 | Upgrade |
Loss (Gain) on Equity Investments | -140.1 | -17.9 | 6.5 | 174.4 | -919.6 | 63.4 | Upgrade |
Other Operating Activities | 1,387 | 1,631 | 1,115 | 982.9 | 905 | 655.4 | Upgrade |
Change in Other Net Operating Assets | 29.2 | 39 | -100.3 | -23.6 | 6.2 | 219 | Upgrade |
Operating Cash Flow | 1,644 | 1,594 | 1,411 | 1,493 | 1,424 | 1,399 | Upgrade |
Operating Cash Flow Growth | 18.71% | 12.91% | -5.48% | 4.89% | 1.80% | -1.82% | Upgrade |
Capital Expenditures | -210.9 | -205.7 | -230.3 | -269.4 | -249.2 | -219.3 | Upgrade |
Sale of Property, Plant & Equipment | 13.2 | 6.8 | 28.4 | 128.3 | 18.7 | 14.6 | Upgrade |
Cash Acquisitions | - | - | - | -95.6 | -400.3 | -1.8 | Upgrade |
Divestitures | - | - | - | 895.7 | - | - | Upgrade |
Investment in Securities | -1,343 | 529 | -1,144 | -100 | -44.2 | 223.7 | Upgrade |
Other Investing Activities | 126.4 | 132.6 | -357.5 | 58.4 | -76 | -37.4 | Upgrade |
Investing Cash Flow | -1,414 | 462.7 | -1,703 | 617.4 | -751 | -20.2 | Upgrade |
Long-Term Debt Issued | - | 1,215 | 1,540 | 729.5 | 1,083 | 1,046 | Upgrade |
Long-Term Debt Repaid | - | -1,002 | -1,135 | -1,027 | -1,700 | -1,561 | Upgrade |
Net Debt Issued (Repaid) | -549.8 | 213.4 | 405.2 | -297 | -617.1 | -515.4 | Upgrade |
Issuance of Common Stock | 2 | 2 | 1.4 | 2.2 | 2.3 | 3.2 | Upgrade |
Repurchase of Common Stock | -36.5 | -91.8 | -18 | -23.2 | -24.7 | - | Upgrade |
Common Dividends Paid | -199.6 | -171.8 | -139.1 | -130.1 | -126.6 | -122.6 | Upgrade |
Other Financing Activities | -606.2 | -613.5 | -453.8 | -354.9 | -322.9 | -244.3 | Upgrade |
Financing Cash Flow | -1,390 | -661.7 | -204.3 | -803 | -1,089 | -879.1 | Upgrade |
Foreign Exchange Rate Adjustments | -87.5 | -17.7 | -41.9 | 24.3 | 15.6 | -37.5 | Upgrade |
Miscellaneous Cash Flow Adjustments | -374.5 | -352 | -323.6 | -298.9 | -267.8 | -202.3 | Upgrade |
Net Cash Flow | -1,622 | 1,025 | -861.8 | 1,033 | -668.5 | 259.5 | Upgrade |
Free Cash Flow | 1,433 | 1,388 | 1,181 | 1,224 | 1,175 | 1,179 | Upgrade |
Free Cash Flow Growth | 19.69% | 17.51% | -3.50% | 4.21% | -0.41% | 2.71% | Upgrade |
Free Cash Flow Margin | 16.76% | 16.79% | 16.14% | 18.14% | 15.65% | 17.26% | Upgrade |
Free Cash Flow Per Share | 33.55 | 32.36 | 26.85 | 27.99 | 26.76 | 26.94 | Upgrade |
Cash Income Tax Paid | 352 | 352 | 323.6 | 299 | 267.8 | 202.2 | Upgrade |
Levered Free Cash Flow | 660.75 | 1,602 | -605.43 | 805.9 | 218.65 | 957.43 | Upgrade |
Unlevered Free Cash Flow | 842.69 | 1,784 | -466.05 | 906.65 | 327.4 | 1,097 | Upgrade |
Change in Net Working Capital | 103 | -971.1 | 1,169 | -212.4 | 346.9 | -375.2 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.